136 related articles for article (PubMed ID: 35359232)
1. Are there country-specific differences in the use of pegvisomant for acromegaly in clinical practice? An analysis from ACROSTUDY.
Grottoli S; Bianchi A; Bogazzi F; Bona C; Carlsson MO; Colao A; Dassie F; Giampietro A; Gomez R; Granato S; Maffei P; Pivonello R; Prencipe N; Ragonese M; Urbani C; Cannavò S
J Endocrinol Invest; 2022 Aug; 45(8):1535-1545. PubMed ID: 35359232
[TBL] [Abstract][Full Text] [Related]
2. Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY.
van der Lely AJ; Biller BM; Brue T; Buchfelder M; Ghigo E; Gomez R; Hey-Hadavi J; Lundgren F; Rajicic N; Strasburger CJ; Webb SM; Koltowska-Häggström M
J Clin Endocrinol Metab; 2012 May; 97(5):1589-97. PubMed ID: 22362824
[TBL] [Abstract][Full Text] [Related]
3. Long-term treatment with pegvisomant as monotherapy in patients with acromegaly: experience from ACROSTUDY.
Freda PU; Gordon MB; Kelepouris N; Jonsson P; Koltowska-Haggstrom M; van der Lely AJ
Endocr Pract; 2015 Mar; 21(3):264-74. PubMed ID: 25370326
[TBL] [Abstract][Full Text] [Related]
4. Pegvisomant treatment in patients with acromegaly in clinical practice: The French ACROSTUDY.
Chanson P; Brue T; Delemer B; Caron P; Borson-Chazot F; Zouater H;
Ann Endocrinol (Paris); 2015 Dec; 76(6):664-70. PubMed ID: 26596374
[TBL] [Abstract][Full Text] [Related]
5. Which patients with acromegaly are treated with pegvisomant? An overview of methodology and baseline data in ACROSTUDY.
Brue T; Castinetti F; Lundgren F; Koltowska-Häggström M; Petrossians P;
Eur J Endocrinol; 2009 Nov; 161 Suppl 1():S11-7. PubMed ID: 19684051
[TBL] [Abstract][Full Text] [Related]
6. The German ACROSTUDY: past and present.
Buchfelder M; Schlaffer S; Droste M; Mann K; Saller B; Brübach K; Stalla GK; Strasburger CJ;
Eur J Endocrinol; 2009 Nov; 161 Suppl 1():S3-S10. PubMed ID: 19684061
[TBL] [Abstract][Full Text] [Related]
7. ACROSTUDY: Status Update on 469 Patients.
Brue T
Horm Res; 2009 Jan; 71 Suppl 1():34-8. PubMed ID: 19153503
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of first-line pegvisomant monotherapy in acromegaly: an ACROSTUDY analysis.
Tritos NA; Chanson P; Jimenez C; King D; Jönsson PJ; Klibanski A; Biller BM
Eur J Endocrinol; 2017 Feb; 176(2):213-220. PubMed ID: 27932529
[TBL] [Abstract][Full Text] [Related]
9. Long-term safety and treatment outcomes of pegvisomant in Japanese patients with acromegaly: results from the post-marketing surveillance.
Yamaguchi H; Shimatsu A; Okayama A; Sato T
Endocr J; 2020 Feb; 67(2):201-210. PubMed ID: 31723069
[TBL] [Abstract][Full Text] [Related]
10. Patient-reported outcomes in patients with acromegaly treated with pegvisomant in the ACROSTUDY extension: A real-world experience.
Salvatori R; Maffei P; Webb SM; Brue T; Loftus J; Valluri SR; Gomez R; Wajnrajch MP; Fleseriu M
Pituitary; 2022 Jun; 25(3):420-432. PubMed ID: 35022929
[TBL] [Abstract][Full Text] [Related]
11. Safety of long-term treatment with Pegvisomant: analysis of Spanish patients included in global ACROSTUDY.
Bernabeu I; Pico A; Venegas E; Aller J; Alvarez-Escolá C; García-Arnés JA; Marazuela M; Jonsson P; Mir N; García Vargas M;
Pituitary; 2016 Apr; 19(2):127-37. PubMed ID: 26553421
[TBL] [Abstract][Full Text] [Related]
12. ACROSTUDY: the first 5 years.
Trainer PJ
Eur J Endocrinol; 2009 Nov; 161 Suppl 1():S19-24. PubMed ID: 19684052
[TBL] [Abstract][Full Text] [Related]
13. Pegvisomant treatment in acromegaly in clinical practice: Final results of the French ACROSTUDY (312 patients).
Barraud S; Caron P; Raingeard I; Lefebvre H; Raverot G; Cortet-Rudelli C; Desailloud R; Henocque R; Brault Y; Brue T; Chanson P; Delemer B
Ann Endocrinol (Paris); 2021 Dec; 82(6):582-589. PubMed ID: 34256010
[TBL] [Abstract][Full Text] [Related]
14. More than a decade of real-world experience of pegvisomant for acromegaly: ACROSTUDY.
Fleseriu M; Führer-Sakel D; van der Lely AJ; De Marinis L; Brue T; van der Lans-Bussemaker J; Hey-Hadavi J; Camacho-Hubner C; Wajnrajch MP; Valluri SR; Palladino AA; Gomez R; Salvatori R
Eur J Endocrinol; 2021 Aug; 185(4):525-538. PubMed ID: 34342594
[TBL] [Abstract][Full Text] [Related]
15. All-cause mortality in patients with acromegaly treated with pegvisomant: an ACROSTUDY analysis.
Tritos NA; Mattsson AF; Vila G; Biller BMK; Klibanski A; Valluri S; Hey-Hadavi J; Kelepouris N; Jimenez C
Eur J Endocrinol; 2020 Mar; 182(3):285-292. PubMed ID: 31917681
[TBL] [Abstract][Full Text] [Related]
16. Does pegvisomant treatment expertise improve control of resistant acromegaly? The Italian ACROSTUDY experience.
Cannavo S; Bogazzi F; Colao A; De Marinis L; Maffei P; Gomez R; Graziano E; Monterubbianesi M; Grottoli S;
J Endocrinol Invest; 2015 Oct; 38(10):1099-109. PubMed ID: 25916431
[TBL] [Abstract][Full Text] [Related]
17. Increasing frequency of combination medical therapy in the treatment of acromegaly with the GH receptor antagonist pegvisomant.
Strasburger CJ; Mattsson A; Wilton P; Aydin F; Hey-Hadavi J; Biller BMK
Eur J Endocrinol; 2018 Apr; 178(4):321-329. PubMed ID: 29371335
[TBL] [Abstract][Full Text] [Related]
18. Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study.
Schreiber I; Buchfelder M; Droste M; Forssmann K; Mann K; Saller B; Strasburger CJ;
Eur J Endocrinol; 2007 Jan; 156(1):75-82. PubMed ID: 17218728
[TBL] [Abstract][Full Text] [Related]
19. A Canadian multi-centre, open-label long-term study of Pegvisomant treatment in refractory acromegaly.
Ezzat S; Gaspo R; Serri O; Ur E; Chik CL
Clin Invest Med; 2009 Dec; 32(6):E265. PubMed ID: 20003832
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance.
Colao A; Pivonello R; Auriemma RS; De Martino MC; Bidlingmaier M; Briganti F; Tortora F; Burman P; Kourides IA; Strasburger CJ; Lombardi G
Eur J Endocrinol; 2006 Mar; 154(3):467-77. PubMed ID: 16498061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]